- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03591913
Preoperative and Postoperative Sublingual Misoprostol for Prevention of Postpartum Blood Loss in Cesarean Section
September 17, 2018 updated by: Ahmed Mohamed Abbas, Assiut University
Comparison Between Preoperative and Postoperative Sublingual Misoprostol for Prevention of Postpartum Blood Loss in Cesarean Section : a Randomized Clinical Trial
Cesarean section is one of the most common major surgical operations among women.
In 2015, the incidence of cesarean section in Woman Health Hospital in Assiut University accounts for 51.3 % of all deliveries
Study Overview
Study Type
Interventional
Enrollment (Actual)
500
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Cairo
-
Assiut, Cairo, Egypt, 002
- Ahmed Abbas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- All pregnant women who will undergo elective lower segment cesarean section
- term ( ≥ 37 weeks)
- normal fetal heart tracing.
Exclusion Criteria:
- Placenta previa-Rupture uterus
- Classical cesarean section
- Preterm delivery
- Hypertensive disorders of pregnancy
- Bleeding tendency
- Previous history of postpartum hemorrhage
- Concurrent anticoagulant therapy
- Concurrent long-term use of steroids
- Fetal distress
- Antepartum haemorrhage
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: study group
will receive sublingual misoprostol immediately after urinary catheterization and before skin incision
|
Oral tablets
|
Active Comparator: control group
will receive sublingual misoprostol immediately after skin closure
|
Oral tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mean intraoperative blood loss
Time Frame: 24 hours
|
Blood loss estimation will commence immediately following the skin incision
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2018
Primary Completion (Actual)
August 1, 2018
Study Completion (Actual)
September 1, 2018
Study Registration Dates
First Submitted
July 8, 2018
First Submitted That Met QC Criteria
July 8, 2018
First Posted (Actual)
July 19, 2018
Study Record Updates
Last Update Posted (Actual)
September 18, 2018
Last Update Submitted That Met QC Criteria
September 17, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Pregnancy Complications
- Obstetric Labor Complications
- Puerperal Disorders
- Uterine Hemorrhage
- Hemorrhage
- Postpartum Hemorrhage
- Physiological Effects of Drugs
- Gastrointestinal Agents
- Reproductive Control Agents
- Anti-Ulcer Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Oxytocics
- Misoprostol
Other Study ID Numbers
- MISOCS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Hemorrhage
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedPostpartum Haemorrhage | Immediate Postpartum HemorrhageFrance
-
University Hospital, Clermont-FerrandUnknownPostpartum Depression | Postpartum Hemorrhage | Postpartum Women | Postpartum Stress | Postpartum AnxietyFrance
-
ResQ Medical LtdNot yet recruitingPPH | Postpartum Hemorrhage \(PPH\) | Postpartum Hemorrhage \(Primary\)Kenya
-
Cairo UniversityUnknownHemorrhage, PostpartumEgypt
-
Columbia UniversityCompletedHemorrhage, PostpartumUnited States
-
Megan LordThermaSENSE CorpCompletedHemorrhage | Vasoconstriction | Hemorrhage, PostpartumUnited States
-
Ain Shams Maternity HospitalUnknownHemorrhage PostpartumEgypt
-
Chelsea and Westminster NHS Foundation TrustCompleted
-
Denver Health and Hospital AuthorityEnrolling by invitationPostpartum Hemorrhage, ImmediateUnited States
-
University Hospital, AngersInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedImmediate Postpartum HemorrhageFrance
Clinical Trials on Misoprostol
-
Aljazeera HospitalKasr El Aini HospitalUnknown
-
Hospital de Clinicas de Porto AlegreCompletedMiscarriage in First TrimesterBrazil
-
Ferring PharmaceuticalsCompletedCervical Ripening | Labor InductionUnited Kingdom
-
Medstar Health Research InstituteSociety of Family PlanningCompletedSecond Trimester AbortionsUnited States
-
Cairo UniversityCompleted
-
Karolinska InstitutetCompletedFirst Trimester Pregnancy | Surgical Termination of PregnancySweden
-
Wenzhou Medical UniversityUnknown
-
CHA UniversityCompleted
-
Rajavithi HospitalCompletedTo Compare Efficacy Intrauterine vs Sublingual MISOPROSTOL in Addition to Oxytocin in Reducing Blood Loss of Post-cesarean Section in High Risk WomenThailand
-
Virginia Commonwealth UniversityCompletedAbortion, Second TrimesterUnited States